# US 2010/0144748 A1 · Methods involving aldose reductase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144748 A1
- Document ID: US20100144748A1
- Status: Published application
- Kind: A1
- Application number: 12/532,553
- Filed: 2008-03-24
- Published: 2010-06-10
- Earliest claimed: 2007-03-23
- Assignees: Board of Regents, The University of Texas System
- Inventors: Satish K. Srivastava
- Web page: https://patentgrep.com/patent/US20100144748A1

## CPC

- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61P 11/06: Antiasthmatics
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12Y 101/01021: Aldehyde reductase (1.1.1.21), i.e. aldose-reductase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.

## Claims

### Claim 1

A method of preventing or reducing uveitis or conjunctivitis in a subject comprising administering to a subject diagnosed with or at risk of developing uveitis or conjunctivitis an amount of a pharmaceutically acceptable composition comprising an aldose reductase inhibitor sufficient to prevent, ameliorate, or attenuate uveitis or conjunctivitis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered one or more times.

### Claim 3 (depends on 1)

The method of claim 1, wherein the aldose reductase inhibitor is administered to the patient as a prodrug.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient is administered the composition directly, locally, topically, orally, endoscopically, intratracheally, intratumorally, intravenously, intralesionally, intramuscularly, intraperitoneally, regionally, percutaneously, or subcutaneously.

### Claim 5 (depends on 4)

The method of claim 4, wherein the aldose reductase inhibitor is administered orally.

### Claim 6 (depends on 1)

The method of claim 1, wherein the aldose reductase inhibitor is a small molecule or an inhibitory RNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the aldose reductase inhibitor is a siRNA or other inhibitory nucleic acid, a carboxylic acid, a hydantoins, a pyridazinone, or a pharmaceutically acceptable derivative thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the aldose reductase inhibitor is sorbinil, epalrestat, ponalrestat, methosorbinil, risarestat, imirestat, ALO-1567, quercetin, zopolrestat, AD-5467, NZ-314, M-16209, minalrestat, AS-3201, WP-921, luteolin, tolrestat, EBPC, fidarestat, and the pharmaceutically acceptable derivatives thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the aldose reductase inhibitor is zopolrestat.

### Claim 10 (depends on 1)

The method of claim 1, wherein the aldose reductase inhibitor is not a nitric oxide inducer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the aldose reductase inhibitor is administered at a dose of 1 to 1500 mg/day.

### Claim 12 (depends on 11)

The method of claim 11, wherein the aldose reductase inhibitor is administered at a dose of 100 to 800 mg/day.

### Claim 13

A method of preventing or reducing asthma associated inflammation in a subject comprising administering to a subject diagnosed with or at risk of developing an inflammatory condition associated with asthma an amount of a pharmaceutically acceptable composition comprising an aldose reductase inhibitor sufficient to prevent, ameliorate, or attenuate inflammation.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition is administered one or more times.

### Claim 15 (depends on 13)

The method of claim 13, wherein the aldose reductase inhibitor is administered to the patient as a prodrug.

### Claim 16 (depends on 13)

The method of claim 13, wherein the patient is administered the composition directly, intrabronchially, intrapleurally, locally, topically, orally, endoscopically, intratracheally, intratumorally, intravenously, intralesionally, intramuscularly, intraperitoneally, regionally, percutaneously, or subcutaneously.

### Claim 17 (depends on 16)

The method of claim 16, wherein the aldose reductase inhibitor is administered by inhalation or instillation.

### Claim 18 (depends on 13)

The method of claim 13, wherein the aldose reductase inhibitor is a small molecule or an inhibitory RNA.

### Claim 19 (depends on 18)

The method of claim 18, wherein the aldose reductase inhibitor is a siRNA, a carboxylic acid, a hydantoins, a pyridazinone, or pharmaceutically acceptable derivative thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the aldose reductase inhibitor is sorbinil, epalrestat, ponalrestat, methosorbinil, risarestat, imirestat, ALO-1567, quercetin, zopolrestat, AD-5467, NZ-314, M-16209, minalrestat, AS-3201, WP-921, luteolin, tolrestat, EBPC, fidarestat, and the pharmaceutically acceptable derivatives thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the aldose reductase inhibitor is zopolrestat.

### Claim 22 (depends on 13)

The method of claim 13, wherein the aldose reductase inhibitor is not a nitric oxide inducer.

### Claim 23 (depends on 13)

The method of claim 13, wherein the aldose reductase inhibitor is administered at a dose of 1 to 1500 mg/day.

### Claim 24 (depends on 23)

The method of claim 23, wherein the aldose reductase inhibitor is administered at a dose of 100 to 800 mg/day.
